Graft Polymer (UK) PLC ( (GB:SVNS) ) has issued an announcement.
Solvonis Therapeutics plc has announced the approval by Awakn Life Sciences Corp.’s security holders for its proposed acquisition of Awakn. This acquisition is a strategic move to enhance Solvonis’ portfolio with clinical-stage assets targeting Alcohol Use Disorder (AUD), a condition affecting millions and inadequately addressed by current treatments. The acquisition includes AWKN-001 and AWKN-002, which are in advanced stages of development and have significant market potential, with comparable assets achieving substantial deal values. The completion of the acquisition is subject to various regulatory approvals and conditions, with an anticipated completion by the end of May 2025.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, with a mission to improve outcomes for individuals suffering from mental health disorders. The company initially focuses on trauma-related mental health conditions, such as PTSD, which affected approximately 13 million adults in the U.S. in 2020, with an estimated current affected population of 20 million across the U.S., UK, and key EU markets.
YTD Price Performance: -40.0%
Average Trading Volume: 8,885,924
Technical Sentiment Signal: Buy
Current Market Cap: £2.76M
For a thorough assessment of SVNS stock, go to TipRanks’ Stock Analysis page.